These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 22272343)

  • 21. Down-regulation of human DAB2IP gene expression mediated by polycomb Ezh2 complex and histone deacetylase in prostate cancer.
    Chen H; Tu SW; Hsieh JT
    J Biol Chem; 2005 Jun; 280(23):22437-44. PubMed ID: 15817459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
    Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
    Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Demethylation of TIMP2 and TIMP3 Inhibits Cell Proliferation, Migration, and Invasion in Pituitary Adenomas.
    Yang Y; Huang F; Wu X; Huang C; Li Y
    Discov Med; 2024 May; 36(184):971-980. PubMed ID: 38798256
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of enhancer of zeste homolog 2 expression in peripheral circulating tumor cells in metastatic prostate cancer patients: a preliminary study.
    Cho KS; Oh HY; Lee EJ; Hong SJ
    Yonsei Med J; 2007 Dec; 48(6):1009-14. PubMed ID: 18159594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
    Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
    J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2.
    Beke L; Nuytten M; Van Eynde A; Beullens M; Bollen M
    Oncogene; 2007 Jul; 26(31):4590-5. PubMed ID: 17237810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic induction of tissue inhibitor of matrix metalloproteinase-3 by green tea polyphenols in breast cancer cells.
    Deb G; Thakur VS; Limaye AM; Gupta S
    Mol Carcinog; 2015 Jun; 54(6):485-99. PubMed ID: 24481780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum.
    Vaillant C; Didier-Bazès M; Hutter A; Belin MF; Thomasset N
    J Neurosci; 1999 Jun; 19(12):4994-5004. PubMed ID: 10366632
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of gelatinases (MMP-2 and MMP-9) and tissue inhibitors of metalloproteinases (TIMP-2 and TIMP-3) in the chicken ovary in relation to follicle development and atresia.
    Hrabia A; Wolak D; Kwaśniewska M; Kieronska A; Socha JK; Sechman A
    Theriogenology; 2019 Feb; 125():268-276. PubMed ID: 30481606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
    Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
    Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Matrix metalloproteinases MMP1, MMP2, MMP9 and their tissue inhibitors TIMP1, TIMP2, TIMP3 in head and neck cancer: an immunohistochemical study.
    Pietruszewska W; Bojanowska-Poźniak K; Kobos J
    Otolaryngol Pol; 2016 Jun; 70(3):32-43. PubMed ID: 27386931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Targeting enhancer of zeste homolog 2 protects against acute kidney injury.
    Zhou X; Zang X; Guan Y; Tolbert T; Zhao TC; Bayliss G; Zhuang S
    Cell Death Dis; 2018 Oct; 9(11):1067. PubMed ID: 30341286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Matrix metalloproteinase-9 expression correlates with prognosis and involved in ovarian cancer cell invasion.
    Hu X; Li D; Zhang W; Zhou J; Tang B; Li L
    Arch Gynecol Obstet; 2012 Dec; 286(6):1537-43. PubMed ID: 22832979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resveratrol inhibits the tumor migration and invasion by upregulating TET1 and reducing TIMP2/3 methylation in prostate carcinoma cells.
    Wang K; Chen Z; Shi J; Feng Y; Yu M; Sun Y; Zhuang Q; Liang B; Luo G; Xu X; Fan M
    Prostate; 2020 Sep; 80(12):977-985. PubMed ID: 32542727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta.
    Cao P; Deng Z; Wan M; Huang W; Cramer SD; Xu J; Lei M; Sui G
    Mol Cancer; 2010 May; 9():108. PubMed ID: 20478051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen-induced alterations in the expression of selected matrix metalloproteinases (MMP-2, -9, -10, and -13) and their tissue inhibitors (TIMP-2 and -3) in the chicken ovary.
    Wolak D; Hrabia A
    Theriogenology; 2020 May; 148():208-215. PubMed ID: 31753476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
    Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
    Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.
    Varambally S; Cao Q; Mani RS; Shankar S; Wang X; Ateeq B; Laxman B; Cao X; Jing X; Ramnarayanan K; Brenner JC; Yu J; Kim JH; Han B; Tan P; Kumar-Sinha C; Lonigro RJ; Palanisamy N; Maher CA; Chinnaiyan AM
    Science; 2008 Dec; 322(5908):1695-9. PubMed ID: 19008416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.